A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). (Q38433690)

From Wikidata

Jump to navigation Jump to search

scientific article published on April 2014

Language	Label	Description	Also known as
English	A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).	scientific article published on April 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

phase II clinical trial

0 references

0 references

triple-negative breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Igor N. Bondarenko

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667715%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

A Awada

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667715%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

J Bonneterre

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667715%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

E Nowara

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667715%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

J M Ferrero

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667715%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

A V Bakshi

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667715%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

C Wilke

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667715%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

M Piccart

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667715%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

CT4002 study group

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667715%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667715%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667715%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667715%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

824-831

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667715%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Molecularly targeted therapies for metastatic triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU025

21 January 2018

Current treatment options in triple negative breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU025

21 January 2018

Neoadjuvant treatments for triple-negative breast cancer (TNBC).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU025

21 January 2018

Adjuvant treatments for triple-negative breast cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU025

21 January 2018

Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU025

21 January 2018

Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU025

21 January 2018

Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU025

21 January 2018

Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU025

21 January 2018

Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU025

21 January 2018

Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU025

21 January 2018

Targeting anticancer drugs to tumor vasculature using cationic liposomes.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU025

21 January 2018

Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU025

21 January 2018

Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU025

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU025

21 January 2018

Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU025

21 January 2018

Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU025

21 January 2018

Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU025

21 January 2018

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU025

21 January 2018

Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU025

21 January 2018

Identifiers

10.1093/ANNONC/MDU025

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667715%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24667715%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38433690&oldid=2111277151"